Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Biol Chem. Nov 27, 2021; 12(6): 104-113
Published online Nov 27, 2021. doi: 10.4331/wjbc.v12.i6.104
Published online Nov 27, 2021. doi: 10.4331/wjbc.v12.i6.104
Neuroprotection by dipeptidyl-peptidase-4 inhibitors and glucagon-like peptide-1 analogs via the modulation of AKT-signaling pathway in Alzheimer’s disease
Yuka Ikeda, Nozomi Nagase, Ai Tsuji, Yasuko Kitagishi, Satoru Matsuda, Food Science and Nutrition, Nara Women’s University, Nara 630-8506, Japan
Author contributions: Each author (Ikeda Y, Nagase N, Tsuji A, Kitagishi Y, Matsuda S) participated sufficiently in this work of drafting the article and/or revising the article for the important rational content; all authors gave final approval of the version to be submitted.
Conflict-of-interest statement: The authors declare that they have no competing financial interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Satoru Matsuda, MD, PhD, Professor, Food Science and Nutrition, Nara Women’s University, Kita-Uoya Nishimachi, Nara 630-8506, Japan. smatsuda@cc.nara-wu.ac.jp
Received: March 26, 2021
Peer-review started: March 26, 2021
First decision: May 6, 2021
Revised: May 21, 2021
Accepted: November 28, 2021
Article in press: November 28, 2021
Published online: November 27, 2021
Processing time: 263 Days and 2.8 Hours
Peer-review started: March 26, 2021
First decision: May 6, 2021
Revised: May 21, 2021
Accepted: November 28, 2021
Article in press: November 28, 2021
Published online: November 27, 2021
Processing time: 263 Days and 2.8 Hours
Core Tip
Core Tip: Disorders of mammalian/mechanistic target of rapamycin (mTOR) signaling pathways are related to Alzheimer’s disease (AD). Although further studies for mTOR, glucagon-like peptide-1, and dipeptidyl-peptidase-4 signaling are needed, they seem to be a promising approach for innovative AD-treatments.